← Back to Search
Melanoma: Oncogenic Drivers And The Immune System.
N. Karachaliou, S. Pilotto, C. Teixidó, S. Viteri, M. Gonzalez-Cao, A. Riso, D. Morales-espinosa, M. Molina, I. Chaib, M. Santarpia, E. Richardet, E. Bria, R. Rosell
Published 2015 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Advances and in-depth understanding of the biology of melanoma over the past 30 years have contributed to a change in the consideration of melanoma as one of the most therapy-resistant malignancies. The finding that oncogenic BRAF mutations drive tumor growth in up to 50% of melanomas led to a molecular therapy revolution for unresectable and metastatic disease. Moving beyond BRAF, inactivation of immune regulatory checkpoints that limit T cell responses to melanoma has provided targets for cancer immunotherapy. In this review, we discuss the molecular biology of melanoma and we focus on the recent advances of molecularly targeted and immunotherapeutic approaches.
This paper references
PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.
M. Scortegagna (2015)
Changes in the number of CD80(+), CD86(+), and CD28(+) peripheral blood lymphocytes have prognostic value in melanoma patients.
J. Martínez-Escribano (2003)
KIT Gene Mutations and Copy Number in Melanoma Subtypes
C. Beadling (2008)
Protein kinases — the major drug targets of the twenty-first century?
P. Cohen (2002)
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
G. Long (2011)
Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Theodore Kouo (2015)
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition
R. Haq (2013)
Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 2004;23:6031-9
H Sumimoto (2004)
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
J. Guo (2011)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
S. Sharma (2010)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
A. Ribas (2015)
Modulation of GITR for cancer immunotherapy.
D. Schaer (2012)
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
S. Hingorani (2003)
Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy.
S. Sebti (2005)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
S. Heidorn (2010)
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
F. S. Hodi (2013)
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
J. F. Jacobs (2012)
The prognostic impact of specific CD4 T-cell responses is critically dependent on the target antigen in melanoma
H. Zelba (2015)
Nivolumab in previously untreated melanoma without BRAF mutation.
C. Robert (2015)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.
M. Ahmadzadeh (2009)
Agonistic CD40 Antibodies and Cancer Therapy
R. Vonderheide (2013)
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
P. Chapman (2011)
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.
Piro Lito (2012)
Sunitinib Therapy for Melanoma Patients with KIT Mutations
D. Minor (2012)
Alternatively Activated Macrophage Possess Antitumor Cytotoxicity That Is Induced by IL-4 and Mediated by Arginase-1
J. Ellyard (2010)
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
H. Rizos (2014)
Activation of N-ras in a human melanoma cell line.
R. Padua (1985)
CD4 cells can be more efficient at tumor rejection than CD8 cells.
A. Perez-Diez (2007)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Ravid Straussman (2012)
KIT as a therapeutic target in metastatic melanoma.
R. Carvajal (2011)
Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion
M. Rangachari (2012)
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
O. Qureshi (2011)
Distribution of latexingesting cells, T cells, and B cells in the peripheral blood of patients with malignant melanoma
B Koziner (1975)
Effective tumor immunotherapy: start the engine, release the brakes, step on the gas pedal,...and get ready to face autoimmunity.
I. Tirapu (2002)
Epigenetic silencing of the PTEN gene in melanoma.
A. Mirmohammadsadegh (2006)
Inhibition of mutated, activated BRAF in metastatic melanoma.
K. Flaherty (2010)
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing
Esther Edlundh-Rose (2006)
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
L. Kwong (2012)
Innate and adaptive immune cells in the tumor microenvironment
T. Gajewski (2013)
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
R. Carvajal (2015)
CD4+CD25+ Suppressor Lymphocytes in the Circulation of Patients Immunized Against Melanoma Antigens
L. Javia (2003)
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity
Mirna Balsamo (2009)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
Tyler R. Simpson (2013)
Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
J. Matsuzaki (2010)
The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells
D. Lindau (2013)
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.
L. Muul (1987)
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
M. Krummel (1995)
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens
E. Baixeras (1992)
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
J. Wilmott (2011)
Aurora Kinase A Messenger RNA Overexpression Is Correlated with Tumor Progression and Shortened Survival in Head and Neck Squamous Cell Carcinoma
R. Reiter (2006)
Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy.
R. Houot (2011)
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
A. Hauschild (2012)
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes
T. Hemesath (1998)
Characterization of the human CD27 ligand, a novel member of the TNF gene family.
R. Hintzen (1994)
A Landscape of Driver Mutations in Melanoma
Eran Hodis (2012)
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
J. Sosman (2012)
Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials
Christine M. Lovly (2012)
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
G. Falchook (2012)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
J. Weber (2015)
Deregulated Akt3 Activity Promotes Development of Malignant Melanoma
J. Stahl (2004)
Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
Lucas Ferrari de Andrade (2014)
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
T. Gajewski (2012)
Densely granulated murine NK cells eradicate large solid tumors.
R. B. Liu (2012)
The GIST paradigm: lessons for other kinase‐driven cancers
C. Antonescu (2011)
Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?
A. Albino (1984)
Malignant melanoma: genetics and therapeutics in the genomic era.
L. Chin (2006)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
X. Jiang (2012)
Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients
J.B.A.G. Haanen (2005)
Adaptive resistance to targeted therapies in cancer.
R. Rosell (2013)
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
M. Ahmadzadeh (2006)
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
T. Milman (2010)
Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives
M. Sanlorenzo (2015)
Evaluation of tumour‐infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases
V. Mourmouras (2007)
The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells
C. Workman (2003)
The immunological synapse
Michael Loran Dustin (2002)
Systemic treatment for BRAF-mutant melanoma: where do we go next?
A. Menzies (2014)
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
J. Müller (2014)
Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma
P. Yuan (2013)
Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Vidhu Sharma (2016)
IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin.
Caroline Hilmi (2008)
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
L. Boussemart (2014)
Mutations of the BRAF gene in human cancer
Helen Davies (2002)
Natural-killer cells and dendritic cells: "l'union fait la force".
T. Walzer (2005)
Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization
Lukas Baitsch (2012)
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
D. Perna (2015)
The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses
Woong-Kyung Suh (2003)
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib
A. Quintás-Cardama (2008)
Tumorinfiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
J Matsuzaki (2010)
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
A. Boni (2010)
The Aurora kinase family in cell division and cancer.
G. Vader (2008)
Advances in protein kinase B signalling: AKTion on multiple fronts.
D. Brazil (2004)
VISTA Regulates the Development of Protective Antitumor Immunity.
I. Le Mercier (2014)
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
E. V. Van Allen (2014)
Dose‐dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
J. Lutzky (2008)
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
M. Holderfield (2014)
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
G. Prendergast (2014)
Major response to imatinib mesylate in KIT-mutated melanoma.
F. S. Hodi (2008)
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.
E. V. Abel (2013)
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
A. Sharpe (2007)
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.
A. Zippelius (2004)
Ran signaling in melanoma: implications for the development of alternative therapeutic strategies.
E. Caputo (2015)
Melanoma immunoediting by NK cells
Mirna Balsamo (2012)
Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference
H. Sumimoto (2004)
Universes collide: combining immunotherapy with targeted therapy for cancer.
J. Wargo (2014)
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Jessie Villanueva (2010)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E. Tivol (1995)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C. Zhu (2005)
Modeling genomic diversity and tumor dependency in malignant melanoma.
W. Lin (2008)
Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand
B. Huard (2004)
Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors.
Yan Ye (2013)
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 2012;13:e32-42
JF Jacobs (2012)
Vemurafenib enhances Karachaliou et al. Molecular biology of melanoma
B Sapkota (2013)
Immune regulation by 4‐1BB and 4‐1BBL: complexities and challenges
C. Wang (2009)
PD‐1 signaling in primary T cells
J. Riley (2009)
Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights
R. Dummer (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
T. Wilson (2012)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
P. Poulikakos (2011)
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
A. Menzies (2012)
Fine tuning the immune response through B7‐H3 and B7‐H4
K. H. Yi (2009)
Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor.
C. Kugel (2014)
Separate GTP binding and GTPase activating domains of a G alpha Karachaliou et al. Molecular biology of melanoma
DW Markby (1993)
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
N. Wagle (2011)
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma
R. Corcoran (2013)
A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.
J. Sosman (2014)
Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway
X. Fang (1999)
Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.
Elisabetta Vergani (2011)
Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
M. Carlino (2014)
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.
A. Rösch (2013)
Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery
S. Datta (1997)
Model predicting survival in stage I melanoma based on tumor progression.
W. Clark (1989)
GAPs in growth factor signalling. Growth factors 2005;23:143-9
A Bernards (2005)
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
S. Quezada (2010)
Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
X. Jiang (2008)
Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
N. Thomas (2015)
Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
C. Miracco (2007)
Somatic activation of KIT in distinct subtypes of melanoma.
J. A. Curtin (2006)
Tumor‐induced immune dysfunction: the macrophage connection
K. Elgert (1998)
Immune checkpoint blockade: a common denominator approach to cancer therapy.
S. Topalian (2015)
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.
Qing-Bai She (2005)
Distinct sets of genetic alterations in melanoma.
J. A. Curtin (2005)
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
Robert J. Johnston (2014)
The CD4-like molecule LAG-3, biology and therapeutic applications
S. Sierro (2011)
The prognostic impact Annals of Translational Medicine, Vol 3, No 18 October 2015 Page 19 of 22 © Annals of Translational Medicine
H Zelba (2015)
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
Y. Shao (2012)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger (2015)
Human Langerhans cells are immature in melanoma sentinel lymph nodes.
G. Gerlini (2012)
Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
M. Callahan (2013)
Recognition of tumors by the innate immune system and natural killer cells.
A. Marcus (2014)
Selective accumulation of differentiated FOXP3+ CD4+ T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood
C. Jandus (2008)
Identification of a Proline-rich Akt Substrate as a 14-3-3 Binding Partner*
K. Kovacina (2003)
Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity
D. Loo (2012)
Mutations in GNA11 in uveal melanoma.
C. D. Van Raamsdonk (2010)
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
K. Paraiso (2010)
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
HGF protects corneal epithelial cells from apoptosis by the PI-3K/Akt-1/Bad- but not the ERK1/2-mediated signaling pathway.
A. Kakazu (2004)
Elucidating distinct roles for NF1 in melanomagenesis.
Ophélia Maertens (2013)
Evolving synergistic combinations of targeted immunotherapies to combat cancer
I. Melero (2015)
RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
P. Poulikakos (2010)
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun (2014)
PRAS40 deregulates apoptosis in malignant melanoma.
S. Madhunapantula (2007)
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
R. Nazarian (2010)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
T. Curiel (2004)
Improvement of Cancer Immunotherapy by Combining Molecular Targeted Therapy
Y. Kawakami (2013)
Orchestrating immune check-point blockade for cancer immunotherapy in combinations.
J. Pérez-Gracia (2014)
Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.
S. Al-Batran (2005)
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.
K. Paraiso (2011)
GAPs in growth factor signalling
A. Bernards (2005)
Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma
H. Zelba (2014)
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Yu-Hwa Huang (2015)
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
P. Ascierto (2013)
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
K. Flaherty (2012)
Improved survival with MEK inhibition in BRAF-mutated melanoma.
K. Flaherty (2012)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
E. Korn (2008)
Second AKT: The rise of SGK in cancer signalling
M. A. Bruhn (2010)
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
G. Long (2014)
Role and therapeutic potential of PI3K‐mTOR signaling in de novo resistance to BRAF inhibition
W. Deng (2012)
Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
H. Shi (2012)
Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis
A. Mansfield (2011)
Uveal melanoma: epidemiologic aspects.
A. Singh (2005)
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
S. Woodman (2009)
Role of ERas in promoting tumour-like properties in mouse embryonic stem cells
Kazutoshi Takahashi (2003)
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
C. Robert (2015)
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
L. Liu (2015)
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations
X. Chen (2014)
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
K. Omholt (2003)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
C. Emery (2009)
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
W. W. Shuford (1997)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
S. Quezada (2006)
The nuts and bolts of AGC protein kinases
Laura R Pearce (2010)
Killer Immunoglobulin-like Receptors and Tumor Immunity
D. Benson (2014)
Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma
A. Rösch (2014)
Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses.
H. Nishimura (1998)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
J. Ellerhorst (2010)
From genes to drugs: targeted strategies for melanoma
K. Flaherty (2012)
Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells
Y. Zheng (2007)
CTLA-4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
SA Quezada (1935)
Function Annals of Translational Medicine, Vol 3, No 18 October 2015 Page 17 of 22 © Annals of Translational Medicine
CH 3rdKugel (2014)
Nivolumab vs. chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
JS Weber (2015)
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
M. Cragg (2008)
BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
H. El-Osta (2011)
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
K. S. Smalley (2009)
Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3
M. Bettini (2011)
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad S Atefi (2014)
Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes.
G. Gerlini (2007)
MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells
L. J. Vella (2014)
Tim-3 inhibits T helper type 1–mediated auto- and alloimmune responses and promotes immunological tolerance
A. Sánchez-Fueyo (2003)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
C. Montagut (2008)
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
F. Romagné (2009)
BRAF alterations are associated with complex mutational profiles in malignant melanoma
M. Daniotti (2004)
Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism1
B. Blazar (2003)
The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
H. Sumimoto (2006)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
L. Wang (2011)
Nilotinib in patients with metastatic melanoma harboring KIT gene aberration
J. Cho (2011)
Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma
F. Hillen (2007)
Collapse of the CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers
E. Carpenter (2009)
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
A. Hauschild (2009)
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A. Postow (2015)
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.
S. Whittaker (2013)
Immunological consequences of selective BRAF inhibitors in malignant melanoma
B. Schilling (2013)
Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.
L. Lauerová (2002)
A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans.
F. I. Staquicini (2008)
Gene-engineered T cells for cancer therapy
M. Kershaw (2013)
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.
Hee-Bum Kang (2015)
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
P. Guldberg (1997)
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.
Lukas Baitsch (2011)
FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.
M. Ahmadzadeh (2008)
Association between natural killer cells and regression in melanocytic lesions.
Kristopher McKay (2011)
Separate GTP binding and GTPase activating domains of a G alpha subunit.
D. W. Markby (1993)
IL-2: The First Effective Immunotherapy for Human Cancer
S. Rosenberg (2014)
B-RAF is a therapeutic target in melanoma
M. Karasarides (2004)
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
T. Okazaki (2013)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
D. Frederick (2013)
Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer
Y. Nadler (2008)
Tumor-specific Th17-polarized cells eradicate large established melanoma.
P. Muranski (2008)
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
S. Hu-Lieskovan (2015)
Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells
B. Sapkota (2013)
Prognostic impact of B-cell density in cutaneous melanoma
A. Ladányi (2011)
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
L. C. Vredeveld (2012)
Melanoma: oncogenic drivers and the immune system
N Karachaliou (2015)
LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice.
T. Miyazaki (1996)
Distribution of latex-ingesting cells, T cells, and B cells in the peripheral blood of patients with malignant melanoma.
B. Koziner (1975)
Anti‐OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses
C. Ruby (2007)
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
M. R. Girotti (2013)
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.
K. Flaherty (2013)
Interferon alpha for the adjuvant treatment of cutaneous melanoma.
S. Mocellin (2013)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
G. Hatzivassiliou (2010)
The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.
M. J. Sale (2013)
Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells1
M. Viguier (2004)
The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population.
E. Hacker (2010)
The BRAFKarachaliou et al. Molecular biology of melanoma © Annals of Translational Medicine
H Sumimoto (2006)
Systemic treatment for BRAFmutant melanoma: where do we go next? Lancet Oncol 2014;15:e371-81
AM Menzies (2014)
Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells.
G. Kalinec (1992)
Major response to everolimus in melanoma with acquired imatinib resistance.
L. Si (2012)
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma
C. Clemente (1996)
Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.
Y. Shao (2010)
Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms.
A. Bonni (1999)
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
X. Zhou (2000)
Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics
D. Frederick (2014)
This paper is referenced by
A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy
Emily J Lelliott (2019)
1α, 25‐Dihydroxyvitamin D3 alters ectonucleotidase expression and activity in human cutaneous melanoma cells
M. Bagatini (2019)
Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma
J. Ang (2017)
A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants
Ivana Tichá (2019)
The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing
M. Yeo (2016)
Investigating the Roles of Fucosylation and Calcium Signaling in Melanoma Invasion
Tyler Keeley (2018)
Immune based therapy for melanoma
Robert Ancuceanu (2016)
Limbic encephalitis following immunotherapy against metastatic malignant melanoma
S. Salam (2016)
Chaperoning STAT3/5 by Heat Shock Proteins: Interest of Their Targeting in Cancer Therapy
Gaëtan Jego (2019)
Immunoregulatory protein B7‐H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells
K. Flem-Karlsen (2017)
NLRC4 suppresses melanoma tumor progression independently of inflammasome activation.
Ann M. Janowski (2016)
Downregulation of β-catenin blocks fibrosis via Wnt2 signaling in human keloid fibroblasts
Yumei Cai (2017)
Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells
M. Tucci (2019)
Immune-competent human skin disease models.
L. Bergers (2016)
Profiling networks of distinct immune-cells in tumors
Trevor Clancy (2016)
Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy.
S. Fendt (2020)
Coptidis Rhizoma induces intrinsic apoptosis through BAX and BAK activation in human melanoma.
Xiaoou Xu (2017)
The Emerging Epigenetic Landscape in Melanoma
R. A. Rollins (2016)